Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study
Infection · 2024-08 · 52 (4) · 1407-1414
DOI: 10.1007/s15010-024-02199-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Infection, online erschienen am 13.03.2024. Verfasst von Kirsten Schmidt-Hellerau und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Ambulatory Care. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Joined Committee, Universitätsklinikum Köln.
Abstract (Originalsprache)
Purpose
Outpatient parenteral antimicrobial therapy (OPAT) offers several key advantages, including enhanced patient quality of life, reduced healthcare costs, and a potential reduction of nosocomial infections. It is acknowledged for its safety and effectiveness. This study provides the first systematic clinical data for Germany, where OPAT has not yet been widely adopted. The aim is to establish a foundational reference point for further research and integration of OPAT into the German healthcare system.
Methods
This prospective observational study descriptively analyses data obtained from a cohort of patients receiving OPAT. Both in- and outpatients from all medical specialties could be recruited. Patients administered the anti-infective medications themselves at home using elastomeric pumps.
Results
77 patients received OPAT, with a median duration of 15 days and saving 1782 inpatient days. The most frequently treated entities were orthopaedic infections ( n = 20, 26%), S. aureus bloodstream infection ( n = 16, 21%) and infectious endocarditis ( n = 11, 14%). The most frequently applied drugs were flucloxacillin ( n = 18, 23%), penicillin G ( n = 13, 17%) and ceftriaxone ( n = 10; 13%). Only 5% of patients ( n = 4) reported to have missed more than one outpatient dose (max. 3 per patient). Only one catheter-related adverse event required medical intervention, and there were no catheter-related infections.
Conclusion
The study demonstrates that OPAT can be safely conducted in Germany. In preparation for its broader implementation, crucial next steps include creating medical guidelines, fostering interdisciplinary and inter-sectoral communication, as well as creating financial and structural regulations that facilitate and encourage the adoption of OPAT. Trial registration number NCT04002453.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Institute of Medical Sociology, Health Services Research and Rehabilitation Science, Chair of Health Services Research, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Department II of Internal Medicine and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Chair of General Practice II and Patient-Centeredness in Primary Care, Institute of General Practice and Primary Care, Faculty of Health, Witten/Herdecke University, Witten, Germany.
- PMV Forschungsgruppe, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Förderung
- German Federal Joined Committee
- Universitätsklinikum Köln
Zitieren
APA
Schmidt-Hellerau, K., Baade, N., Günther, M., Scholten, N., Lindemann, C. H., Leisse, C., Oberröhrmann, C., Peter, S., Jung, N., Suarez, I., Horn, C., Ihle, P., Küpper-Nybelen, J., Hagemeier, A., Hellmich, M., & Lehmann, C. (2024). Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study. Infection, 52(4), 1407-1414. https://doi.org/10.1007/s15010-024-02199-9
Vancouver
Schmidt-Hellerau K, Baade N, Günther M, Scholten N, Lindemann CH, Leisse C, et al. Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study. Infection. 2024;52(4):1407-1414. doi:10.1007/s15010-024-02199-9
BibTeX
@article{SchmidtHellerau2024,
author = {Schmidt-Hellerau, Kirsten and Baade, Nina and Günther, Marina and Scholten, Nadine and Lindemann, Christoph Heinrich and Leisse, Charlotte and Oberröhrmann, Charlotte and Peter, Sophie and Jung, Norma and Suarez, Isabelle and Horn, Carola and Ihle, Peter and Küpper-Nybelen, Jutta and Hagemeier, Anna and Hellmich, Martin and Lehmann, Clara},
title = {Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study},
journal = {Infection},
year = {2024},
volume = {52},
number = {4},
pages = {1407--1414},
doi = {10.1007/s15010-024-02199-9}
}
EUVIMED